To the Editor: We would like to thank Dr. Querques for his interest in our article. We read with interest the case report entitled "Correspondence: Recalcitrant macular edema after intravitreal bevacizumab is responsive to an intra-vitreal dexamethasone implant in retinal vein occlusion" written by Querques et al. It would seem that the patient in their report was undeitreated based on the interval of injections. As the authors noted, Ozurdex was the only Food and Drug Administration-approved drug for retinal vein occlusion when treatment of the patient began. However, the most optimal effective duration of Ozurdex is1 month to 4 months, with peak concentrations of the medicine in the vitreous cavity occurring at roughly2 months after the injection.2"5 The clinical trial data clearly show loss of efficacy by the 6-month time point, supporting more frequent injections in those cases where edema persists or recurs.It is unclear how the fluorescein angiogram images would have appeared, had the patient been evaluated at an earlier date after treatment with Ozurdex rather than at 6 months after treatment.
展开▼
